Clinical outcomes of descemet membrane endothelial keratoplasty using the bonfadini-todd injector for graft insertion

Research output: Contribution to journalArticle

Abstract

Purpose: To evaluate the clinical outcomes of using an Alcon intraocular lens (IOL) B cartridge for graft insertion during Descemet membrane endothelial keratoplasty (DMEK). Patients and methods: We retrospectively reviewed medical charts of patients who underwent DMEK using the Bonfadini-Todd injector, composed of an Alcon IOL B cartridge connected to plastic tubing and a syringe, for graft insertion between May 2016 and August 2018. Patient demographics, diagnoses, donor information, visual acuity, intraocular pressure (IOP), graft position and attachment status, pachymetry, and postoperative complications were recorded. Results: Twenty-four eyes of 23 patients with an average age of 72.8 ± 10.0 years (range, 48-87 years) were included. Mean follow-up duration was 13.3 ± 6.6 months (range, 3-26 months). Twenty-one (87.5%) patients had a primary diagnosis of Fuchs endothelial dystrophy, two (8.3%) patients had bullous keratopathy and one (4.2%) had Peter’s anomaly. Sixteen (66.7%) cases combined phacoemulsification and IOL implantation. Best-corrected visual acuity improved from a median of 0.398 logMAR preoperatively to 0.097 logMAR (P <0.001) at last follow-up examination, and central corneal thickness decreased from a median of 651 µm to 533.5 µm (P <0.001). Nine of 24 patients (37.5%) required re-bubbling due to partial graft detachment with a mean time of 12.1 ± 9.2 days (range, 5-35 days). One patient (4.2%) developed graft failure after re-bubbling and underwent Descemet stripping endothelial keratoplasty. Conclusion: The Alcon IOL B cartridge for DMEK graft insertion is safe and simple.

Original languageEnglish (US)
Pages (from-to)1869-1876
Number of pages8
JournalClinical Ophthalmology
Volume13
DOIs
StatePublished - Jan 1 2019

Fingerprint

Descemet Membrane
Corneal Transplantation
Transplants
Intraocular Lenses
Visual Acuity
Descemet Stripping Endothelial Keratoplasty
Fuchs' Endothelial Dystrophy
Intraocular Lens Implantation
Phacoemulsification
Syringes
Intraocular Pressure
Plastics
Demography
Tissue Donors

Keywords

  • Corneal transplantation
  • Descemet membrane endothelial keratoplasty
  • DMEK injector

ASJC Scopus subject areas

  • Ophthalmology

Cite this

@article{eaa31ad85c6d48b6878ea593df5cda54,
title = "Clinical outcomes of descemet membrane endothelial keratoplasty using the bonfadini-todd injector for graft insertion",
abstract = "Purpose: To evaluate the clinical outcomes of using an Alcon intraocular lens (IOL) B cartridge for graft insertion during Descemet membrane endothelial keratoplasty (DMEK). Patients and methods: We retrospectively reviewed medical charts of patients who underwent DMEK using the Bonfadini-Todd injector, composed of an Alcon IOL B cartridge connected to plastic tubing and a syringe, for graft insertion between May 2016 and August 2018. Patient demographics, diagnoses, donor information, visual acuity, intraocular pressure (IOP), graft position and attachment status, pachymetry, and postoperative complications were recorded. Results: Twenty-four eyes of 23 patients with an average age of 72.8 ± 10.0 years (range, 48-87 years) were included. Mean follow-up duration was 13.3 ± 6.6 months (range, 3-26 months). Twenty-one (87.5{\%}) patients had a primary diagnosis of Fuchs endothelial dystrophy, two (8.3{\%}) patients had bullous keratopathy and one (4.2{\%}) had Peter’s anomaly. Sixteen (66.7{\%}) cases combined phacoemulsification and IOL implantation. Best-corrected visual acuity improved from a median of 0.398 logMAR preoperatively to 0.097 logMAR (P <0.001) at last follow-up examination, and central corneal thickness decreased from a median of 651 µm to 533.5 µm (P <0.001). Nine of 24 patients (37.5{\%}) required re-bubbling due to partial graft detachment with a mean time of 12.1 ± 9.2 days (range, 5-35 days). One patient (4.2{\%}) developed graft failure after re-bubbling and underwent Descemet stripping endothelial keratoplasty. Conclusion: The Alcon IOL B cartridge for DMEK graft insertion is safe and simple.",
keywords = "Corneal transplantation, Descemet membrane endothelial keratoplasty, DMEK injector",
author = "Mehrnaz Ighani and Sezen Karakus and Eghrari, {Allen O.}",
year = "2019",
month = "1",
day = "1",
doi = "10.2147/OPTH.S219742",
language = "English (US)",
volume = "13",
pages = "1869--1876",
journal = "Clinical Ophthalmology",
issn = "1177-5467",
publisher = "Dove Medical Press Ltd.",

}

TY - JOUR

T1 - Clinical outcomes of descemet membrane endothelial keratoplasty using the bonfadini-todd injector for graft insertion

AU - Ighani, Mehrnaz

AU - Karakus, Sezen

AU - Eghrari, Allen O.

PY - 2019/1/1

Y1 - 2019/1/1

N2 - Purpose: To evaluate the clinical outcomes of using an Alcon intraocular lens (IOL) B cartridge for graft insertion during Descemet membrane endothelial keratoplasty (DMEK). Patients and methods: We retrospectively reviewed medical charts of patients who underwent DMEK using the Bonfadini-Todd injector, composed of an Alcon IOL B cartridge connected to plastic tubing and a syringe, for graft insertion between May 2016 and August 2018. Patient demographics, diagnoses, donor information, visual acuity, intraocular pressure (IOP), graft position and attachment status, pachymetry, and postoperative complications were recorded. Results: Twenty-four eyes of 23 patients with an average age of 72.8 ± 10.0 years (range, 48-87 years) were included. Mean follow-up duration was 13.3 ± 6.6 months (range, 3-26 months). Twenty-one (87.5%) patients had a primary diagnosis of Fuchs endothelial dystrophy, two (8.3%) patients had bullous keratopathy and one (4.2%) had Peter’s anomaly. Sixteen (66.7%) cases combined phacoemulsification and IOL implantation. Best-corrected visual acuity improved from a median of 0.398 logMAR preoperatively to 0.097 logMAR (P <0.001) at last follow-up examination, and central corneal thickness decreased from a median of 651 µm to 533.5 µm (P <0.001). Nine of 24 patients (37.5%) required re-bubbling due to partial graft detachment with a mean time of 12.1 ± 9.2 days (range, 5-35 days). One patient (4.2%) developed graft failure after re-bubbling and underwent Descemet stripping endothelial keratoplasty. Conclusion: The Alcon IOL B cartridge for DMEK graft insertion is safe and simple.

AB - Purpose: To evaluate the clinical outcomes of using an Alcon intraocular lens (IOL) B cartridge for graft insertion during Descemet membrane endothelial keratoplasty (DMEK). Patients and methods: We retrospectively reviewed medical charts of patients who underwent DMEK using the Bonfadini-Todd injector, composed of an Alcon IOL B cartridge connected to plastic tubing and a syringe, for graft insertion between May 2016 and August 2018. Patient demographics, diagnoses, donor information, visual acuity, intraocular pressure (IOP), graft position and attachment status, pachymetry, and postoperative complications were recorded. Results: Twenty-four eyes of 23 patients with an average age of 72.8 ± 10.0 years (range, 48-87 years) were included. Mean follow-up duration was 13.3 ± 6.6 months (range, 3-26 months). Twenty-one (87.5%) patients had a primary diagnosis of Fuchs endothelial dystrophy, two (8.3%) patients had bullous keratopathy and one (4.2%) had Peter’s anomaly. Sixteen (66.7%) cases combined phacoemulsification and IOL implantation. Best-corrected visual acuity improved from a median of 0.398 logMAR preoperatively to 0.097 logMAR (P <0.001) at last follow-up examination, and central corneal thickness decreased from a median of 651 µm to 533.5 µm (P <0.001). Nine of 24 patients (37.5%) required re-bubbling due to partial graft detachment with a mean time of 12.1 ± 9.2 days (range, 5-35 days). One patient (4.2%) developed graft failure after re-bubbling and underwent Descemet stripping endothelial keratoplasty. Conclusion: The Alcon IOL B cartridge for DMEK graft insertion is safe and simple.

KW - Corneal transplantation

KW - Descemet membrane endothelial keratoplasty

KW - DMEK injector

UR - http://www.scopus.com/inward/record.url?scp=85073465143&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85073465143&partnerID=8YFLogxK

U2 - 10.2147/OPTH.S219742

DO - 10.2147/OPTH.S219742

M3 - Article

C2 - 31571824

AN - SCOPUS:85073465143

VL - 13

SP - 1869

EP - 1876

JO - Clinical Ophthalmology

JF - Clinical Ophthalmology

SN - 1177-5467

ER -